| Treatment regimen (subgroup analysis with simultaneous ISC-Qu) (initial sample size 318 (106 vs. 212)) |
Value (test)
ISC-Qu
group
% or mean
(± SD) |
Value
control group
% or mean
(± SD) |
Valid N test / control group |
p-value
(Chi-Square, Fisher’s or Mann-Whitney- exact test) |
| Radiation therapy received %
(including any combination) |
40.0 |
29.2 |
105 / 212 |
0.058 |
| Chemotherapy received %
(including any combination) |
98.1 |
94.8 |
106 / 212 |
0.232 |
| Chemotherapy: 5-FU / pyrimidines % |
97.2 |
93.4 |
106 / 212 |
0.194 |
| Chemotherapy: platin-based drugs % |
2.8 |
5.2 |
106 / 212 |
0.400 |
| Chemo- / radiotherapy (ONC) %
Only radiotherapy %
Only chemotherapy %
Chemo- and radiotherapy combined % |
100.0
1.9
60.0
38.1 |
100.0
5.2
70.8
24.1 |
105 / 212
2 / 11
63 / 150
40 / 51 |
0.023 |
| Chemotherapy: 1st course duration: mean (SD), (months) |
5.2 (3.3) |
5.8 (3.1) |
104 / 198 |
0.006 |
| Chemo-/radiotherapy (ONC) total duration: mean, (SD), (months), |
8.5 (11.5) |
8.7 (12.4) |
106 / 204 |
0.059 |
| ISC-Qu: overall therapy duration:
median, (range), (months) |
54 (11-141) |
n/a |
106 |
n/a |
| Cumulative ISC-Qu dose (mg):
mean (SD), [median (range)] |
4299 (2349)
[4221 (696-10523)] |
n/a |
106 |
n/a |
| Estimated mean weekly ISC-Qu dose (mg), mean (SD), [median (range)] |
16.2 (6.4)
[17 (2-37.7)] |
n/a |
106 |
n/a |
